SERBIAN MEDICAL SOCIETY
ONCOLOGY SECTION

UMSTBS SECTION OF
NURSES IN ONCOLOGY

62ND ONCOLOGY CONGRESS

BELGRADE | SERBIA

38TH SYMPOSIUM OF ONCOLOGY NURSES-TECHNICIANS OF SERBIA

NOVEMBER 12–15th 2025 • SAVA CENTER • BELGRADE, SERBIA

62nd ONCOLOGY CONGRESS

November 12–15th 2025
Sava Center, Belgrade, Serbia

Congress organizer

Serbian Medical Society Oncology Section
Address: Džordža Vašingtona 19, 11000 Belgrade, Serbia
Telephone: +381 11 3234-450
kanceroloskasekcijasld@gmail.com (office)

President of the Oncology Section and Congress President
Professor dr Ivan Marković
ivanmarkovic66@yahoo.com

Secretary of the Oncology Section and Congress Secretary
Assistant prof. dr Nada Santrač
santrac.nada@gmail.com

Congress co-organizers

INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE

SSSO Serbian Society of Surgical Oncology

UMOS

ARCUS

CoMP

International endorsement

esso The European Society of Surgical Oncology Endorsed

European School of Oncology

Executive organizer

ASTAKOS TRAVEL & EVENTS

NOVI ASTAKOS
congress@astakos.com; www.astakos.com
Telephone: +381 63 337 808, +381 63 232 663

Digital support

IMT

Inovativne medicinske terapije – Udruženje za savremenu prevenciju i terapiju bolesti
info@imt.edu.rs; www.imt.edu.rs
Telephone: +381 64 466 8878

Dear Colleagues,

It is our great pleasure to welcome you to the **62nd Oncology Congress**, organized by the **Serbian Medical Society Oncology Section**, in collaboration with the **Institute for Oncology and Radiology of Serbia** and several esteemed national societies, including the **Serbian Society of Medical Oncology (UMOS)**, **Serbian Society of Surgical Oncology (SSSO)**, **Association of Radiation Oncologists of Serbia (AROS)**, and the **Serbian Association for Cancer Research (SDIR)**. The Congress will be held from **November 12–15, 2025**, at the **Sava Center in Belgrade, Serbia**.

We are proud to announce that this year's meeting has received **two prestigious international endorsements** — from the **European Society of Surgical Oncology (ESSO)** and the **European School of Oncology (ESO)**.

As in previous years, the **scientific program** is comprehensive, diverse, and truly multidisciplinary. Over four days, it will encompass a broad range of topics, with a focus on **innovations in diagnostics and treatment** across major tumor types, including breast, lung, digestive, gynecological, and hematological malignancies. Special sessions will be devoted to **hereditary and early-onset cancers**, **oncofertility**, and the **role of artificial intelligence in healthcare**, as well as the **importance of research collaboration in oncology**, and the **novelties in radiotherapy**, including **total body irradiation**.

We are honored to host distinguished keynote speakers — **Professor Alberto Costa (Italy)**, **Professor Charles Balch (USA)**, **Dr. Thomas Hofmarcher (Sweden)**, and **Dr. Mef Nilbert (Sweden)** — who will address some of the most pressing issues in oncology today, including **screening**, **health economics**, **paradigm shifts in breast cancer treatment**, and **future perspectives in oncology**.

One of the "hot topics" of this year's Congress will be the **exclusive presentations of three new national guidelines** for the **diagnosis and treatment of breast cancer, melanoma, and cancer-associated thrombosis**, followed by expert panel discussions.

Marking **two decades since the founding of the UMOS**, a dedicated session will celebrate the Society's 20th anniversary, reflecting on its achievements and exploring its current and future directions.

The **19th Cancer Patients' Forum** will once again provide a vital platform for patient engagement, addressing topics of great importance such as the role of empathy and information in effective healthcare communication, breast cancer treatment during pregnancy, and personal experiences shared by a breast cancer survivor. In the spirit of **multidisciplinarity and teamwork**, **oncology nurses and technicians** from across Serbia will also participate, hosting their **38th Symposium** on **November 14–15, 2025**.

With its long-standing tradition, multidisciplinary approach, and internationally recognized speakers, the Oncology Congress in Belgrade continues to serve as **one of the most significant regional events in oncology.**

On behalf of the **Scientific Committee of the 62nd Oncology Congress**, we express our sincere gratitude to all **international and national speakers, panelists, and participants**

for sharing their expertise and contributing to the exchange of knowledge within the oncology community of Serbia and the region. We also wish to thank our **industry partners** for their continuous support and for joining us in our shared mission — **to improve patient care and outcomes through continuous professional development and innovation.**

Together, we can continue to **reshape the future of oncology in Serbia and beyond**.

Welcome!



Professor dr Ivan Marković
Serbian Medical Society Oncology Section President
62nd Oncology Congress President



Assistant prof. dr Nada Santrač
Serbian Medical Society Oncology Section Secretary
62nd Oncology Congress Secretary

62nd ONCOLOGY CONGRESS

November 12–15th 2025
Sava Center, Belgrade, Serbia

Scientific and Organizing Committee

Ivan Marković, Congress President
Nada Santrač, Congress Secretary

Davorin Radosavljević, UMOS President
Srđan Nikolić, SSSO President
Suzana Stojanović Rundić, AROS President
Milena Čavić, SDIR President

Snežana Šušnjar
Marijana Milović Kovačević
Ivana Božović Spasojević
Lazar Popović
Jelena Spasić
Bojan Zarić
Radmila Janković
Mirjan Nadrljanski
Marina Nikitović
Tatjana Arsenijević
Darko Antić
Marija Ristić
Tatjana Stanojković
Ana Krivokuća
Ana Jovićević
Mila Purić

62nd ONCOLOGY CONGRESS

12–15th November 2025

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 1, November 12th 2025, WEDNESDAY

HALL A		
08:00–09:00	Registration and refreshments	
09:00–11:00	**Congress opening** Ivan Marković, Nada Santrač, Special guests	
	KEYNOTE LECTURE **Economic perspective of cancer treatments – cost or investment?** Thomas Hofmarcher (Sweden)	
	KEYNOTE LECTURE **New Suggested National Swedish Cancer Strategy** Mef Nilbert (Sweden)	
	HOT TOPIC **National Guidelines for Diagnostics and Treatment of Breast Cancer – where are we now and what are the future perspectives?** Ferenc Vicko	
11:00–11:45	**Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration** **Part 1: Diagnostics** Moderators: Mirjan Nadrljanski, Nada Santrač	
11:00–11:20	Optimizing Axillary Assessment: Imaging Strategies for Accurate Nodal Staging in Early Breast Cancer	Mirjan Nadrljanski
11:20–11:45	Panel discussion: Marijana Milović Kovačević, Merima Goran, Olivera Ivanov, Dejan Dimitrijević	
11:45–12:00	Coffee break	
12:00–12:45	**Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration** **Part 2: Surgery** Moderators: Ivan Marković, Nada Santrač	
12:00–12:20	De-escalating Axillary Surgery: Balancing Oncologic Safety and Quality of Life in Early Breast Cancer	David Pinto (Portugal)

12:20–12:45	Panel discussion: Ferenc Vicko, Marko Buta, Marko Spasić
12:45–13:15	**Sponsored symposium 1** **ROCHE** **Integration of Genomic Medicine into the Serbian Healthcare System** Moderator: Branka Zukić From Pilot Project to Systemic Transformation of the Healthcare Ecosystem – Branka Zukić, Milica Kontić
13:15–14:15	Lunch
14:15–15:00	**Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration** **Part 3: Systemic treatment** Moderators: Marijana Milović Kovačević, Milana Matović
14:15–14:30	Beyond positive axillary lymph nodes – when do we go bigger in systemic treatments? Marijana Milović Kovačević
14:30–15:00	Panel discussion: Gorana Matovina Brko, Tatjana Ivković Kapicl, Nada Santrač
15:00–16:00	**Sponsored symposium 2** **Novartis** **Opening and Introduction: Setting the Stage and Addressing Unmet Need in HR+/HER2-eBC** Moderator: Ivana Božović Spasojević NATALEE 5-year outcomes – Lazar Popović High risk N+ patients: Evaluating treatment efficacy – Marijana Milović Kovačević N0 NATALEE data: Why is it important to treat N0 HR+/HER2-EBC at high risk of recurrence – Dejan Jurić Ribociklib: Unique characteristics in EBC therapy – Ana Cvetanović Discussion
16:00–16:15	Coffee break
16:15–16:50	**Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration** **Part 4: Radiotherapy** Moderators: Jasmina Mladenović, Simonida Bobić
16:15–16:30	Omission or de-escalation of radiotherapy in early breast cancer conservative treatment Olivera Ivanov
16:30–16:50	Panel discussion: Aleksandar Ranković, Neda Milosavljević
16:50–17:55	**Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration** **Part 5: Survivorship** Moderators: Nada Santrač, Marijana Milović Kovačević

16:50–17:10	Life After Breast Cancer: Redefining Survivorship in the Era of Precision Medicine	Antonio Di Meglio (France)
17:10–17:25	Panel discussion: Joseph Gligorov (France), Ivan Marković, Tanja Španić EUROPA DONNA (Slovenia), Nina Kovačević (Slovenia), Ana Jovićević	
17:25–17:40	Early Integrated Rehabilitation for Genitourinary Syndrome of Menopause in Breast Cancer Patients in Slovenia	Nina Kovačević (Slovenia)
17:40–17:55	Panel discussion: Antonio Di Meglio (France), Joseph Gligorov (France), Tanja Španić EUROPA DONNA (Slovenia), Ana Jovićević	
17:55–18:00	Break	
18:00–19:15	**20 years of Serbian Society of Medical Oncology (UMOS)** Moderators: Zoran Tomašević, Nenad Milanović, Siniša Radulović, Davorin Radosavljević	
18:00–18:10	Why do we need UMOS?	Davorin Radosavljević
18:10–18:20	Why is UMOS necessary for researchers?	Milena Čavić
18:20–18:35	The Long Road to Personalized Oncology: Will the Next 20 Years Follow the Same Path?	Lazar Popović
18:35–19:15	Panel discussion: Between ESMO, NCCN and RFHI – what are the biggest achievements of Serbian oncology? Moderator: Ivana Božović Spasojević Panelists: Zoran Andrić, Suzana Matković, Marijana Milović Kovačević, Jelena Spasić, Ljiljana Stamatović, Ana Cvetanović	
19:15–19:30	Break	
19:30	**Welcome cocktail (Atrium)**	
	HALL B	
11:00–12:00	**HOT TOPICS IN LUNG CANCER 1** **Big things in small-cell** Moderator: Bojan Zarić	
11:00–11:20	New era of SCLC treatment – an orphan no more?	Carles Escriu (UK)
11:20–11:40	Challenges of radiotherapy in the new era of SCLC treatment	Tatjana Arsenijević
11:40–12:00	Panel discussion: Marina Cekić, Katja Mohorčić (Slovenia), Tatjana Bošković, Carles Escriu (UK)	

12:00–12:45	**Sponsored symposium 1** **ROCHE** **Mission for brightness in SCLC** Moderator: Jelena Spasić SCENE of local clinical practice – Jelena Spasić Navigating to the NorthStar in SCLC galaxy – Carles Escriu Spotlight on long term responders – Zoran Andrić New horizons in SCLC treatment landscape – Bojan Zarić	
12:45–13:00	Coffee break	
13:00–14:10	**HOT TOPICS IN LUNG CANCER 2** **Evolving treatment paradigms in early stage disease** Moderator: Jelena Spasić	
13:00–13:15	IO in early stage non-oncogene addicted NSCLC: neoadjuvant or perioperative, is there a standard?	Bojan Zarić
13:15–13:30	Early stage oncogene-addicted NSCLC – moving towards a new standard of care?	Daliborka Bursać
13:30–13:45	ctDNA and MRD in early-stage NSCLC: ready for prime-time?	Feđa Đorđević
13:45–14:10	Panel discussion: Bojan Zarić, Nebojša Marić, Dejan Stojiljković, Tatjana Arsenijević, Natalija Samardžić	
14:10–15:00	Lunch	
15:00–15:30	**Sponsored symposium 2** **MSD** **Where science meets practice: Keytruda® (pembrolizumab) case highlights from young lung cancer physicians** Moderator: Jelena Spasić Panelists: Katarina Ljujić, Nikola Marić, Jelena Mikov	
15:30–16:40	**HOT TOPICS IN LUNG CANCER 3** **Evolving treatment paradigms in early stage disease** Moderator: Bojan Zarić	
15:30–15:45	Unresectable NSCLC – what is new?	Aleksandar Stepanović
15:45–16:00	Toxicity and quality of life when using IO in early stage NSCLC: issues for survivorship	Jelena Spasić
16:00–16:15	Using IO in metastatic disease after treatment of early stage: do we have enough data	Katja Mohorčić (Slovenia)
16:15–16:40	Panel discussion: Feđa Đorđević, Marta Velinović, Daliborka Bursać, Goran Stojanović	
16:40–17:00	Coffee break	

17:00–17:30	**Sponsored symposium 3** **Pfizer** **Expert Panel Meeting – From principles to practice: Enhancing the patient experience in ALK+ aNSCLC** Moderator: Bojan Zarić Panelists: Natalija Samardžić, Marija Peulić
17:30–18:00	**Sponsored symposium 4** **Johnson&Johnson** **mNSCLC with EGFRm: Rybrevant® (amivantamab) as an answer to the unmet need** mNSCLC – Diagnostic challenges and therapeutic gaps – Goran Stojanović Clinical significance of Rybrevant® in NSCLC with EGFR exon20 insertion – Biljana Filipović Amivantamab with chemotherapy: A new chance after osimertinib – Zoran Andrić Discussion
18:00–18:30	**Sponsored symposium 5** **PharmaSwiss** **Antiemetic strategy in modern oncology: Adapting therapy to new protocols** Moderator: Snežana Bošnjak CINV – Recommendations for antiemetics use in MASCC ESMO 2023 guideline – Jelena Dimitrijević Prevention of nausea and vomiting induced by ADCs – Snežana Bošnjak Q&A
19:30	**Welcome cocktail (Atrium)**

62nd ONCOLOGY CONGRESS

12–15th November 2025

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 2, November 13th 2025, THURSDAY

	HALL A	
08:00–09:00	Oral presentations of selected abstracts	
09:00–09:40	**KEYNOTE LECTURE** **Future of Oncology** Charles Balch (USA)	
09:40–10:30	**Pregnancy after breast cancer diagnosis – outpatients oncofertility clinic IORS** Moderators: Nataša Lazin, Snežana Šušnjar	
09:40–09:55	Support for young women with breast cancer who desire having children – our experience	Nataša Lazin
09:55–10:10	Safety of temporarily interrupting endocrine therapy for pregnancy – what have we learnt from ETOP-IBCSG Positive study	Snežana Šušnjar
10:10–10:30	Discussion	
10:30–10:45	Coffee break	
10:45–12:15	**Metastatic Breast Cancer 1** **The Art of Sequencing: Clinical and Scientific Perspectives in HR+ Metastatic Breast Cancer** Moderators: Lazar Popović, Ivana Božović Spasojević	
10:45–11:00	Refining Treatment Strategies: Targeted Therapies in HR+/HER2– Metastatic Breast Cancer	Joseph Gligorov (France)
11:00–11:15	Discussion	
11:15–11:30	Decoding the Genome: Precision Insights in HR+/HER2– Metastatic Breast Cancer	Dejan Jurić (USA)
11:30–11:45	Discussion	
11:45–12:00	PARP Inhibitors and beyond in the treatment of Metastatic HR+ Breast Cancer with BRCA mutation	Assia Konsoulova (Bulgaria)

12:00–12:15	Discussion	
12:15–13:00	**Sponsored symposium 1** **ROCHE** **A commitment to the future – Tailoring Care for HR+ metastatic breast cancer** Moderator: Ivana Božović Spasojević Redefining hope: Showing the unmet need in HR+ metastatic breast cancer – Ana Cvetanović PI3Ki: Continued efforts are showing success - Dejan Jurić Current guidelines in managing patients with HR+/HER2- mBC – Ivana Božović Spasojević	
13:00–13:10	Coffee break	
13:10–13:55	**Sponsored symposium 2** **Pfizer** **One day on the Clinic: Navigating Clinical Scenarios to Individualize Care in HR+/HER2-mBC** Moderator: Lazar Popović Panelists: Ivana Božović Spasojević, Gorana Matovina Brko, Marija Andrijić	
14:00–15:00	Lunch	
15:00–16:00	**Metastatic Breast Cancer 2** **Redefining HER2 Negativity: New Insights, New Targets** Moderators: Marijana Milović Kovačević, Vladimir Todorović	
15:00–15:15	HER2 low and ultra-low expression – high expectations and ultra-high standards	Svitlana Bachurska (Bulgaria)
15:15–15:25	Panel discussion: Tatjana Ivković Kapicl, Duško Dunđerović, Ivana Minić	
15:25–15:40	New treatment strategies with ADCs in HR+/HER2- metastatic breast cancer	Ana Cvetanović
15:40–16:00	Panel discussion: Svitlana Bachurska (Bulgaria), Ivana Minić	
16:00–17:00	**Sponsored symposium 3** **AstraZeneca** **Leading with Purpose: Enhertu Across the HER2 Spectrum in mBC.** ***One therapy. One vision.*** Moderator: Marijana Milović Kovačević Speakers: Lazar Popović, Tatjana Ivković Kapicl, Ana Cvetanović, Ivana Božović Spasojević	

17:00–17:45	**Sponsored symposium 4** **Eli Lilly** **Verzenios is the only CDK4/6 inhibitor with a proven overall survival benefit in the curative setting and 2 years of treatment** Moderator: Ivana Božović Spasojević Identifying and acting on High-Risk of recurrence in patients with HR+, HER2-EBC with nodal involvement – Ana Cvetanović Verzenios delivers sustained IDFS benefit and OS benefit with 2 years of treatment – Lazar Popović	
17:45–18:00	Coffee break	
18:00–18:30	**Hematological malignancies 1** **Multiple myeloma: where are we now?** Moderators: Mila Purić, Jelena Bila	
18:00–18:20	The state-of-the-art in multiple myeloma treatment	Jelena Bila
18:20–18:30	Panel discussion: Jelena Bila, Mila Purić, Nada Vlaisavljević	
18:30–19:10	**Hematological malignancies 2** **Lymphoma highlights** Moderator: Mila Purić	
18:30–18:40	Novelties in follicular lymphoma therapy	Maja Popović
18:40–18:50	Novelties in the therapy of diffuse B large cell lymphoma	Mila Purić
18:50–19:00	CART in the treatment of follicular and diffuse B large cell lymphoma	Ivan Petković
19:00–19:10	Panel discussion: Maja Popović, Ivan Petković, Dušan Ristić, Mila Purić	
	HALL B	
08:30–09:00	Oral presentations of selected abstracts	
09:00–09:30	Break	
09:30–10:15	**Hepatocellular carcinoma** Moderator: Marija Ristić	
09:30–09:45	Imaging diagnostics of HCC: is biopsy necessary?	Dragan Vasin
09:45–10:00	Systemic treatment of advanced HCC	Ivan Nikolić
10:00–10:15	Panel discussion: Vladimir Cvetić, Miljana Džunić, Nenad Mijalković	
10:15–11:15	**Sponsored symposium 1** **AstraZeneca** **IMFINZI Across the Cancer Continuum** Moderator: Lazar Popović Panelists: Bojan Zarić, Marijana Milovič Kovačević, Suzana Matković, Feđa Đorđević	

11:15–11:30	Coffee break	
11:30–12:30	**Cholangiocellular carcinoma** Moderator: Srđan Nikolić	
11:30–11:55	Challenges and novelties in diagnostics of cholangiocellular carcinoma	Jelena Kovač
11:55–12:10	Cholangiocellular carcinoma in the era of targeted treatments	Nebojša Manojlović
12:10–12:30	Panel discussion: Zoran Andrić, Nataša Prvulović Bunović, Neda Nikolić, Radmila Janković	
12:30–13:20	**Metastatic disease** Moderator: Marija Ristić	
12:30–12:42	Evolving treatment of metastatic pancreatic cancer	Marina Marković
12:42–12:54	SBRT of liver metastases	Srđan Milanović
12:54–13:06	ALPPS Procedure in the Management of Borderline Resectable Liver Lesions	Vladimir Jokić
13:06–13:20	Panel discussion: Mlađan Protić, Sanja Kostić, Biljana Šeha	
13:20–14:15	Lunch	
14:15–15:00	**Sponsored symposium 2** **Amicus** **Optimizing Outcomes in mCRC: Evidence-Based Insights on Vectibix** Understanding Metastatic Colorectal Cancer: Challenges and Advances – Ivan Nikolić Optimizing Treatment of mCRC with Vectibix – Zafir Murtezani Clinical Insights on Vectibix: Evidence from the PARADIGM Trial – Nenad Mijalković Managing Adverse Effects Associated with Anti-EGFR Treatment – Miljana Džunić	
15:00–16:00	**Colorectal Cancer** Moderators: Dragan Radovanović, Marko Dožić	
15:00–15:10	Neoadjuvant Approach in Locally Advanced Rectal Cancer: Clinical Standards and the Potential Role of Liquid Biopsy	Mladen Marinković
15:10–15:25	Modern Concept of CRC Treatment – Evolution of the Continuum	Marija Ristić
15:25–15:40	Cytoreductive Surgery and HIPEC in Colorectal Cancer: Evolving Evidence and Emerging Insights	Milan Kocić
15:40–16:00	Panel discussion: Miljan Ćeranić, Saša Jungić, Srđan Nikolić	
16:00–16:10	Coffee break	

16:10-16:55	**Sponsored symposium 3** **Takeda** **Fruquintinib: Advancing the Treatment of mCRC** Moderator: Zoran Andrić Zoran Andrić – Unmet needs in later lines of mCRC treatment Ivan Nikolić – FRESCO and FRESCO-2: the path to a new therapeutic option Marija Ristić – Sequencing strategy in later lines of treatment for patients with mCRC in Serbia Nenad Mijalković – A new therapeutic option: patient selection, timing, and rationale	
16:55–17:00	Break	
17:00–17:30	**Sponsored symposium 4** **Servier** **Shaping the Future of Gastrointestinal Cancer Treatment** Moderator: Zoran Andrić Welcome and Introduction – Zoran Andrić Advances in the Treatment of Metastatic Colorectal Cancer: Optimization of Treatment Options – Neda Nikolić Latest Advances in the Treatment of Metastatic Pancreatic Cancer: Improving Treatment Practice – Bogdan Bogdanović Panel Discussion: all participants Concluding Remarks – Zoran Andrić	
17:30–18:00	**Sponsored symposium 5** **Novartis** **Castration-resistant Prostate Cancer – Integrating Nuclear Medicine and Oncology perspectives** Marina Krneta Popović, Suzana Matković	
18:00–18:15	**Sponsored symposium 6** **Merck** **Advancements in Therapeutic Strategies for mCRC: Results from Two Phase III Studies** Marija Ristić	
18:15–18:30	Coffee break	
18:30–20:00	**19th PATIENTS' FORUM** Moderators: Svetlana Berat, Ana Jovićević, Dragana Jovićević	
18:30–18:50	Empathy and information – pillars of quality communication in healthcare	Sara Bojanić
18:50–19:10	Return to work after breast cancer treatment – the voice of a female patient from Serbia	Mirjana Branković Magić
19:10–19:30	Treatment of breast cancer in pregnancy	Snežana Šušnjar
19:30–20:00	Q&A	

62nd ONCOLOGY CONGRESS

12–15th November 2025

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 3, November 14th 2025, FRIDAY

HALL A

08:00–09:00	Oral presentations of selected abstracts	
09:00–09:30	**KEYNOTE LECTURE** **Lifetime journey and paradigm shift in breast cancer understanding and treatment** Alberto Costa, ESO (Italy)	
09:30–10:30	**Special panel** **Innovating together: when research meets clinical practice** Moderator: Branka Zukić	
	Panelists: Marijana Milović Kovačević, Miljana Tanić, Jadranka Mirković	
10:30–10:40	Coffee break	
10:40–11:35	**Scientific projects in Serbia** Moderators: Ivana Božović Spasojević, Radmila Janković	
10:40–10:55	2023–2026: Detection and quantification of residual disease in patients with high-risk and advanced melanoma as a marker of therapy response and prognosis (ReDiMEL); PRIZMA; Fond za nauku Republike Srbije (Beograd)	Lidija Kandolf
10:55–11:10	2023–2026: Advancing REversible immunocapture toward SCALablE EV purification (RESCALE-EV); PRIZMA; Fond za nauku Republike Srbije (Beograd) 2025–2028: EXPANDing the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healthcare (EXPAND-EV); Horizont Evropa, MSCA Staff Exchange; Evropska lecture komisija (Brisel, Belgija)	Milica Popović
11:10–11:25	MiNe2Brain, Development of an innovative platform consisting of lipid-polymer hybrid nanoparticles and microneedles for targeted brain delivery of novel GABAkines favored by reverse transport; DIJASPORA 2023; Fond za nauku Republike Srbije (Beograd)	Miroslav Savić

11:25–11:35	Discussion	
11:35–12:25	**Special panel** **Artificial intelligence: reshaping the landscape and horizons of oncology** Moderators: Mirjan Nadrljanski, Nada Santrač	
11:35–11:50	AI in screening	Mirjan Nadrljanski
11:50–12:10	AI in surgical oncology	Pedro Gouveia (Portugal)
12:10–12:15	Reshaping oncology through diagnostic precision	Ana Luisa Palacios Acedo, Lunit Inc (online)
12:15–12:25	Discussion and conclusions: Steps towards clinical implementation of AI in Serbia	Jelena Bojović, Office for Information Technologies and e-Government
12:25–13:10	**Sponsored symposium 1** **MSD** **Integrated Approaches to Improving Cancer Care Outcomes in Serbia: Prevention, Early Diagnosis, and Treatment as a Path to Systemic Solutions** Moderator: Marijana Milović Kovačević Panelists: Bojan Zarić, Ana Cvetanović, Zoran Andrić, Thomas Hofmarcher	
13:10–14:10	Lunch	
14:10–16:00	**When Cancer Comes Early: New Perspectives on Young-Onset Malignancies** Moderators: Jelena Spasić, Ivana Božović Spasojević	
14:10–14:25	Rising Tide: Tackling the Challenge of Early-Onset Cancers in breast cancer	Ivana Božović Spasojević
14:25–14:35	Discussion	
14:35–14:50	Rising Tide: Tackling the Challenge of Early-Onset Cancers in lung cancer	Jelena Spasić
14:50–15:00	Discussion	
15:00–15:15	Rising Tide: Tackling the Challenge of Early-Onset Cancers in colorectal cancer	Neda Nikolić
15:15–15:25	Discussion	
15:25–15:40	Rising Tide: Tackling the Challenge of Early-Onset Cancers in gynecological cancers	Marta Nerone (Switzerland)
15:40–15:50	Discussion	

15:50–16:50	**Sponsored symposium 2** **Amicus** **The CheckMate Series: Redefining Standards in Oncology** Neoadjuvant Immunochemotherapy for NSCLC – Findings from CheckMate 816 – Bojan Zarić CheckMate-9LA: Dual Immunotherapy and Chemotherapy in First-Line NSCLC – Zoran Andrić 1L Urothelium: CheckMate 901 Study Outcomes – Suzana Matković CheckMate 214: Transforming First-Line RCC Therapy – Maja Popović Opdivo Plus Chemo: Key Findings from CheckMate-649 – Marija Ristić	
16:50–17:00	Coffee break	
17:00–18:40	**From 3D-CRT, IMRT, and VMAT to Proton and Hadron Therapy: Shaping the Future of Radiotherapy** Moderators: Marina Nikitović, Tatjana Stanojković	
17:00–17:15	Modern radiotherapy – what does the future offer us	Aleksandar Stepanović
17:15–17:30	Advancing Cancer Care Through Particle Therapy	Angelica Facoetti (Italy)
17:30–17:45	The Slovenian proton therapy project	Mark Pleško (Slovenia)
17:45–18:00	Proton therapy – clinical aspects	Jelena Bokun
18:00–18:15	RadExIORSBoost Exploring Individual Radiosensitivity: A Voyage Through RNA and miRNA Universe	Nina Petrović
18:15–18:30	The Role of Tumor-Derived Exosomal miRNAs in the Tumor Microenvironment and Circulating Cell Signaling	Ivan Jovanović
18:30–18:40	Discussion	

62nd ONCOLOGY CONGRESS

12–15th November 2025

Sava Center, Belgrade, Serbia

SCIENTIFIC PROGRAM

DAY 4, November 15th 2025, SATURDAY

HALL A		
08:00–08:30	Oral presentations of selected abstracts	
08:30–09:40	**Cancer-Associated Thrombosis: From Mechanisms to Risk Stratification and Clinical Management – Promotion of National Guidelines for CAT** Moderator: Darko Antić	
08:30–08:35	Address by a representative of the Ministry of Health	
08:35–08:40	Address by a representative of the Serbian Medical Society Academy of Medical Sciences	
08:40–08:45	Address by a guideline reviewer	
08:45–09:40	Panel discussion: Snežana Bošnjak, Jelena Dimitrijević, Darko Antić, Mirjana Mitrović, Nikica Sabljić, Nikola Pantić	
09:40–10:00	Coffee break	
10:00–10:35	**HOT TOPIC** **National Guidelines for Diagnostics and Treatment of Melanoma – current possibilities and perspective** Moderators: Ivan Marković, Borislava Nikolin	
10:00–10:10	Overview of current recommendations	Suzana Matković
10:10–10:20	Melanoma surgery in the era of modern therapies	Ivan Marković
10:20–10:35	Discussion	
10:35–11:20	**Sponsored symposium** **MSD** **Clinical Experiences with Immunotherapy in the Treatment of Melanoma and Triple-Negative Breast Cancer** Moderators: Ivana Božović Spasojević, Suzana Matković Panelists: Marina Petronijević, Nemanja Kolović	
11:20–11:30	Coffee break	
11:30–13:00	**Genetic testing protocols for hereditary breast cancer: Steps toward equal access and consistent implementation of guidelines nationwide** Moderators: Ana Krivokuća, Snežana Šušnjar	

11:30–11:40	Hereditary breast cancer in Serbia – prevalence and current testing protocol	Marija Đorđić Crnogorac
11:40–11:50	Indications for panel testing of hereditary breast cancer – new guidelines	Ana Krivokuća
11:50–12:05	Genetic testing for hereditary breast cancer through therapeutic indications (application of new drugs)	Snežana Šušnjar
12:05–12:15	Discussion	
12:15–12:30	Experiences with genetic testing of hereditary mutations and plans for implementing new protocols – Novi Sad	Tatjana Ivković Kapicl
12:30–12:45	Experiences with genetic testing of hereditary mutations and plans for implementing new protocols – Niš	Ana Cvetanović
12:45–13:00	Discussion	
13:00–14:00	Lunch	
14:00–14:50	**Endometrial Cancer: From Molecular Classification to Multimodal Therapy** Moderator: Anđela Karaferić	
14:00–14:10	The Role of Sentinel Lymph Node Biopsy in Staging and Therapeutic Decision-Making in Endometrial Cancer	Petar Radlović
14:10–14:20	Postoperative Radiotherapy for Endometrial Cancer: New ESGO/ESTRO/ESP Guidelines and Controversies in the Adjuvant Setting	Bojan Todorović
14:20–14:30	Recent Advances in Systemic Therapy for Recurrent and Metastatic Endometrial Cancer: Insights from the DUO-E Trial	Simonida Bobić
14:30–14:50	Panel discussion: Ognjen Živković, Stefan Joksimović, Milana Matović, Mirjana Miković, Katarina Stefanović	
14:50–15:00	Coffee break	
15:00–16:00	**Cervical Cancer: De-escalation, Innovation, and Integration in Modern Management** Moderator: Marijana Milović Kovačević	
15:00–15:10	Surgical De-escalation in Low-Risk Early Cervical Cancer	Bojana Gutić

15:10–15:20	Approaches to the Management of Locally Advanced Cervical Cancer: INTERLACE vs EMBRACE I vs KEYNOTE-A18	Olivera Ivanov
15:20–15:30	Key Insights into Brachytherapy from the EMBRACE II Study	Mirjana Miković
15:30–15:40	Final Overall Survival Analysis from the KEYNOTE-826 Study	Marijana Milović Kovačević
15:40–16:00	Panel discussion: Aleksandar Tomašević, Stefan Joksimović, Ilinka Todorovska, Lidija Pavlović, Irena Conić, Marija Živković	
16:00–17:10	**Total Body Irradiation (TBI)** Moderator: Tatjana Arsenijević	
16:00–16:10	Principles of Hematopoietic Stem Cell Transplantation	Milena Todorović Balint
16:10–16:20	Modern Techniques of TBI	Tatjana Arsenijević
16:20–16:30	Role of the Medical Physicist in Planning and Delivery of TBI	Snežana Voštinić
16:30–16:40	Experience of Institute for Oncology and Radiology of Serbia in Implementing TBI	Aleksandar Stepanović
16:40–16:50	Experience of University Hospital Center Zagreb in Implementing TBI	Lea Galunić Bilić (Croatia)
16:50–17:10	Panel discussion: Milena Todorović Balint, Aleksandar Stepanović, Ivana Mišković	
17:10	**Closing remarks and congress evaluation**	

38. SIMPOZIJUM MEDICINSKIH SESTARA-TENHIČARA ONKOLOŠKIH INSTITUCIJA REPUBLIKE SRBIJE

12–15. novembar 2025. • „Sava centar“ • Beograd, Srbija

Dragan Kodžo
Predsednik Sekcije sestara u onkologiji UMSTBS

Slađana Sokolović
Sekretar Sekcije sestara u onkologiji UMSTBS

Stručni odbor

Mirjana Gavrilović, predsednik
Jasmina Paunković
Suzana Momčilović-Stojković
Melita Memiši
Dragan Kodžo
Vera Mandić
Dragana Mušikić Kraker
Danica Pavlović
Slađana Sokolović
Snežana Čurić
Nataša Bakić
Jelica Perović
Tanja Šljivić-Bojić
Vesna Radojičić
Sandra Spajić

Organizacioni odbor

Slađana Sokolović, predsednik
Mirjana Gavrilović
Jelisaveta Vidosavljević
Anđela Vujanac
Anastazija Raičković
Danica Jevđić

Poštovane koleginice i kolege,

Sa velikim zadovoljstvom najavljujemo 38. Simpozijum medicinskih sestara i tehničara onkoloških institucija Republike Srbije, koji se održava pod pokroviteljstvom Komore medicinskih sestara i tehničara Srbije, u Sava Centru u Beogradu, tradicionalno u okviru 62. Kancerološke nedelje (12–15. novembar 2025. godine).

Plenarna tematika ovogodišnjeg Simpozijuma odvijaće se kroz rad tri okrugla stola prevenciju, lečenje i zdravstvenu negu obolelih od malignih bolesti ženskih reproduktivnih organa; značaj TBI (zračenja celog tela) kod hematoloških pacijenata kroz prikaz dosadašnjih iskustava; kao i ciljanu („target“) terapiju kao inovativni pristup u lečenju malignih bolesti, uz poseban osvrt na ulogu onkološke sestre u postizanju boljih ishoda lečenja.

Osim plenarnih predavanja, rad na Simpozijumu će se odvijati kroz brojne usmene prezentacije u okviru okruglog stola „Iskustva u kliničkoj praksi medicinskih sestara i tehničara u onkologiji“ (slobodne teme), gde će učesnici iz Republike Srbije i zemalja regiona predstaviti svoja stručna iskustva i primere iz prakse sa inovativnim pristupima u lečenju, zbrinjavanju i zdravstvenoj nezi onkoloških pacijenata.

Cilj nam je da i ove godine okupimo što veći broj medicinskih sestara, tehničara i drugih zdravstvenih radnika iz Srbije i regiona, radi razmene iskustava iz svih oblasti ovog važnog i velikog segmenta medicinske i javnozdravstvene delatnosti. Simpozijum već dugi niz godina pruža priliku učesnicima da steknu nova znanja, aktivno učestvuju u usmenim i poster prezentacijama, diskusijama u sesijama i doprinesu razvoju zdravstvene nege u onkologiji.

Simpozijum je akreditovan od strane Zdravstvenog saveta Srbije pod brojem **D-1-457/25** kao Nacionalni simpozijum sa:

8 bodova za predavače

7 bodova za usmene prezentacije

5 bodova za poster prezentacije

4 boda za pasivno učešće

Dobrodošli!



Mirjana Gavrilović,
predsednik Stručnog odbora



Slađana Sokolović,
sekretar Sekcije sestara u onkologiji
predsednik Organizacionog odbora



Dragan Kodžo
predsednik Sekcije
sestara u onkologiji

38. SIMPOZIJUM MEDICINSKIH SESTARA-TENHIČARA ONKOLOŠKIH INSTITUCIJA REPUBLIKE SRBIJE

„Novine u zdravstvenoj nezi i lečenju onkoloških pacijenata“

NAUČNI PROGRAM

POKROVITELJ: **Komora medicinskih sestara i zdravstvenih tehničara Srbije**

1. dan, petak, 14. novembar 2025.		
08:30–14:00	**Registracija učesnika**	
09:30–10:00	**Svečano otvaranje 38. Simpozijuma**	
10:00–10:10	**Značaj TBI (zračenje celog tela) kod hematoloških pacijenata – naša iskustva** (uvodna reč moderatora)	Moderator: Tanja Šljivić Bojić
10:10–10:20	**Uloga TBI u sklopu kondicioniranja kod alogene transplantacije** (predavanje)	Milena Todorović Balint
10:20–10:30	**Zadaci medicinske sestre-tehničara u pripremi pacijenata za alogenu transplantaciju matičnih ćelija hematopoeze – TBI** (predavanje)	Tanja Šljivić Bojić
10:30–10:40	**Zračenje celog tela (TOTAL BODY IRRADIATION) – savremene mogućnosti** (predavanje)	Tatjana Arsenijević, Aleksandar Stepanović, Marina Nikitović
10:40–10:50	**Planiranje, sprovođenje i verifikacija tretmana zračenja celog tela (TBI) – aktivnosti strukovnog medicinskog radiologa** (predavanje)	Milovan Vasiljević
10:50–11:00	Diskusija	
11:00–11:10	Kafe pauza	

11:10–11:20	**Prevencija, lečenje i zdravstvena nega obolelih od malignih bolesti ženskih reproduktivnih organa** (uvodna reč moderatora)	Moderator: Maja Urošević Janković
11:20–11:30	**Epidemiologija i prevencija malignih bolesti ženskih reproduktivnih organa** (predavanje)	Vera Mandić, Jelena Lazić, Ana Jovićević, Danica Pavlović
11:30–11:40	**Značaj molekularnog testiranja kod karcinoma ovarijuma u svetlu novih terapijskih opcija** (predavanje)	Marijana Topalović
11:40–11:50	**Hirurško lečenje i zdravstvena nega obolelih od malignih bolesti ženskih reproduktivnih organa** (predavanje)	Maja Urošević Janković
11:50–12:00	**Primena hemioterapije neposredno nakon citoreduktivne hirurgije u hipertermijskim uslovima** (predavanje)	Novica Radovanović, Jovan Filipović, Duško Radivojević
12:00–12:10	**Specifičnosti lečenja i zdravstvene nege kod pacijentkinja sa malignitetom ženskih reproduktivnih organa** (predavanje)	Jasmina Mitrović
12:10–12:20	**Radioterapijski protokol za pozicioniranje, imobilizaciju i verifikaciju ginekološke regije** (predavanje)	Jelena Nidžović
12:20–12:30	**Rana rehabilitacija nakon hirurškog lečenja obolelih od malignih bolesti ženskih reproduktivnih organa** (predavanje)	Dušanka Ćupić
12:30–12:40	Diskusija	
12:40–13:40	Pauza za ručak	
13:40–13:50	**Iskustva u kliničkoj praksi medicinskih sestara-tehničara u onkologiji** (uvodna reč moderatora)	Moderator: Jelena Ivanović
13:50–13:57	**Zdravstvena nega pacijenta u toku radioterapijskog tretmana karcinoma prostate – prikaz slučaja** (usmena prezentacija)	Anđela Vujanac

13:57–14:04	**Pristup medicinske sestre u multidisciplinarnoj nezi deteta sa sarkomom vagine** (usmena prezentacija)	Vanja Milošević, Milica Kosanović
14:04–14:11	**Dvojna kontrola – zlatni standard u primeni hemoterapije** (usmena prezentacija)	Irena Jovanovska Barishikj
14:11–14:18	**Hiruško lečenje melanoma vulve – prikaz slučaja** (usmena prezentacija)	Natalija Pavlović, Katarina Kostić, Marija Popović
14:18–14:25	**Prevencija, lečenje i zdravstvena nega obolelih od malignih bolesti ženskih reproduktivnih organa** (usmena prezentacija)	Emilija Marinković
14:25–14:32	**Seksualna disfunkcija kod pacijentkinja sa karcinomom ginekoloških organa** (usmena prezentacija)	Maja Jovanovski, Jasna Petrov, Jelena Stepanović
14:32–14:39	**Uloga medicinske sestre u prevenciji, lečenju i zdravstvenoj nezi obolelih od karcinoma grlića materice** (usmena prezentacija)	Lela Samardžiev
14:39–14:46	**Leukoneutropenija kod pacijentkinja sa karcinomom grlića materice na konkomitantnom hemio i radioterapijskom tretmanu – sestrinski aspekti** (usmena prezentacija)	Jovana Stojkov, Jasna Petrov, Jelena Stepanović
14:46–14:56	Kafe pauza	
14:56–15:03	**Prenatalna zdravstvena nega trudnica sa malignim oboljenjem** (usmena prezentacija)	Amina Hurem, Milena Maričić
15:03–15:10	**Zdravstvena nega tokom porođaja kod onkoloških pacijentkinja** (usmena prezentacija)	Miljana Mijić, Vanja Pažun
15:10–15:17	**Brahiterapija kod pacijentkinja sa malignitetom ginekološke regije** (usmena prezentacija)	Lepa Petrašinović, Beba Planinčić
15:17–15:24	**Primena HPV vakcina kao prevencija raka grlića materice** (usmena prezentacija)	Vesna Tatomirović
15:24–15:31	**Kompetencije medicinske sestre pri primeni imunoterapije kod dece obolele od neuroblastoma – Dinutuximab** (usmena prezentacija)	Milica Kosanović, Vanja Milošević

15:31–15:38	**Sestrinske intervencije kod pacijenata sa srčanom insuficijencijom obolelih od malignih bolesti** (usmena prezentacija)	Živka Šumaković
15:38–15:50	Diskusija	
	2. dan, subota, 15. novembar 2025.	
09:00–11:30	**Registracija učesnika**	
09:15–09:25	**Ciljana „target“ terapija – inovativni pristup u lečenju malignih bolesti – uloga onkološke sestre u postizanju boljih ishoda lečenja** (uvodna reč moderatora)	Moderator: Melita Memiši
09:25–09:35	**Ciljana terapija BRCA mutiranog karcinoma dojke – uloga onkološke sestre u postizanju boljih ciljeva** (predavanje)	Gorica Marinković
09:35–09:45	**Personalizovani pristup u onkološkoj nezi pacijenata sa HER 2 pozitivnim karcinomom dojke** (predavanje)	Aleksandra Ninković
09:45–09:55	**Sestrinski pristup i podrška pacijentima obolelim od karcinoma pluća u primeni inovativnih terapija** (predavanje)	Milena Lovas
09:55–10:05	**Imunološki posredovan hepatitis kao neželjena reakcija imunoterapije – pembrolizumab – prikaz slučaja** (predavanje)	Elmira Kojčin
10:05–10:15	**Imunoterapija i maligne bolesti – izazovi u lečenju i zdravstvenoj nezi** (predavanje)	Sanela Mitrović
10:15–10:25	**Inovativna terapija kod pacijenata sa metastatskim hormosenzitivnim karcinomom prostate – naša iskustva** (predavanje)	Nina Mrđa
10:25–10:35	Diskusija	
10:35–10:55	**Nova dimenzija lečenja** **Trening subkutane administracije leka** Kompanija Roche Srbija – štand (demonstracija veština)	Melita Memiši, Sanja Jelić
10:55–11:05	Kafe pauza	

11:05–11:15	**Iskustva u kliničkoj praksi medicinskih sestara – tehničara u onkologiji** (uvodna reč moderatora)	Moderator: Anđela Vujanac
11:15–11:22	**Intraoperativna primena indocijanin zelene u onkološkoj hirurgiji – aspekt instrumentarke** (usmena prezentacija)	Marija Popović, Katarina Kostić, Viktorija Jovanović
11:22–11:29	**Primena Tebentafusp (KIMMTRAK) kod pacijenata sa uvealnim melanomom – sestrinski aspekti** (usmena prezentacija)	Tatjana Petković
11:29–11:36	**Uloga medicinske sestre tokom izvođenja PUNCH biopsije** (usmena prezentacija)	Anđelina Sević
11:36–11:43	**Ishrana i maligne bolesti** (usmena prezentacija)	Slavica Janković
11:43–11:50	**Ciljana terapija HR-pozitivnog HER2-negativnog metastatskog karcinoma dojke – sestrinski aspekt** (usmena prezentacija)	Gorica Marinković, Anastazija Raičković
11:50–11:57	**Uloga MST u lečenju obolelih od metastatskog karcinoma bubrega inovativnom target terapijom** (usmena prezentacija)	Marko Pavlović
11:57–12:04	**Neželjeni efekti radioterapijskog tretmana uz primenu Cetuksimaba kod pacijenata sa malignim tumorima glave i vrata – prikaz slučaja** (usmena prezentacija)	Jelisaveta Vidosavljević
12:04–12:11	**Primena Brentuximab-vedotin (ADCETRIS) kod relaps refraktarnim Hodkinovim limfomom – sestrinski aspekti** (usmena prezentacija)	Ana Milovanović
12:11–12:18	**Uticaj imunoterapije na kvalitet života bolesnika obolelih od melanoma** (usmena prezentacija)	Srđan Veselinović
12:18–12:25	**Primena Daratumubaba (DATZALEX) kod bolesnika sa relapsom multiplog mijeloma – sestrinski aspekti** (usmena prezentacija)	Sanela Arsić

12:25–12:32	**Nega rane nakon mastektomije dojke – dužnosti medicinske sestre** (usmena prezentacija)	Sara Atanasijević
12:32–12:39	**Papilarni karcinom štitaste žlezde kod dece uzrasta od 5 godina** (usmena prezentacija)	Jovana Lišanin, Katarina Kostić, Marija Živković
12:39–12:46	**MRI TRACTOGRAPHY** (usmena prezentacija)	Aleksandra Pantelić
12:46–12:53	**Značaj ranog prepoznavanja simptoma neuropatije izazvane taksanskom hemioterapijom** (usmena prezentacija)	Miloš Maljik
12:53–13:05	Diskusija	
13.05–13:15	**Evaluacija Simpozijuma**	
13:15–13:25	**Zaključci Simpozijuma**	
13:25–14:25	Ručak	

Samo za stručnu javnost

Roche

Radimo danas ono što je pacijentima potrebno sutra.

Roche je globalna biotehnološka kompanija sa sedištem u Švajcarskoj, poznata po inovacijama u oblasti farmacije i dijagnostike.



Roche kombinuje lekove, dijagnostičke alate i digitalna rešenja kako bi omogućio personalizovanu medicinu i preciznije terapije.

Nauka, inovacija, posvećenost.

Roche d.o.o. I Vladimira Popovića 8a, Novi Beograd I +381 11 20 22 803

M-RS-00004224

We are leading a revolution in oncology to redefine cancer care

AstraZeneca

IMJUDO® tremelimumab

Lynparza® olaparib

ENHERTU® trastuzumab deruxtecan

IMFINZI® durvalumab

TAGRISSO® osimertinib

CALQUENCE® acalabrutinib



AstraZeneca

Predstavništvo AstraZeneca UK Limited Beograd
Milutina Milankovića 1i, Beograd
Tel: 011 3336 900
SAMO ZA STRUČNU JAVNOST
RS-7716, novembar 2025.

Pre propisivanja lekova kompanije AstraZeneca, molimo pročitajte poslednje odobrene sažetke karakteristika lekova: Enhertu®, Sažetak karakteristika leka, jun 2025. Lynparza®, Sažetak karakteristika leka, jul 2025. Imfinzi®, Sažetak karakteristika leka, septembar 2025. Imjudo®, Sažetak karakteristika leka, januar 2025. Tagrisso®, Sažetak karakteristika leka, februar 2025. Calquence®, Sažetak karakteristika leka, avgust 2022.

KEYTRUDA®

(pembrolizumab)



MERCK SHARP & DOHME D.O.O.
Omladinskih brigada 90a/1400
Beograd-Novi Beograd, Srbija
tel: 011 44 10 200; fax: 011 44 10 203

Samo za stručnu javnost.
Pre propisivanja MSD lekova, molimo Vas da proučite Sažetak karakteristika leka.
Režim izdavanja leka: Lek se može upotrebljavati samo u stacionarnoj zdravstvenoj ustanovi

Veeva code: RS-KEY-00574| Pripremljeno u Srbiji: Jul 2025.
Copyright ©2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

KISQALI®
ribociclib

Powerful Consistency

Lilly
A MEDICINE COMPANY

PREDSTAVNIŠTVO ELI LILLY (SUISSE) S.A.
Vladimira Popovića 38-40, Beograd (Novi Beograd)
Republika Srbija

NOTES

NOTES

NOTES

NOTES

NOTES

PLATINUM SPONSORS

Roche

AstraZeneca

MSD

GOLD SPONSOR

NOVARTIS

SILVER SPONSOR

Pfizer

BRONZE SPONSOR

Lilly
A MEDICINE COMPANY

SPONSORS

AMICUS
a Swixx BioPharma company

Takeda

Johnson&Johnson

Hemofarm
STADA GROUP

PHARMASWISS

SERVIER
moved by you

MERCK

GENOPHARM

OKTAL PHARMA

B|BRAUN
SHARING EXPERTISE

Slaviamed
PHARMACEUTICALS

NeoMedica
PROMET MEDICINSKIM MATERIJALOM